Skip to main content

2019 Payers' Guide Mid-Year Addendum

FDA Approvals
Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy
Lilly Ostrovsky
Read More
FDA Approvals
Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL
Lilly Ostrovsky
Read More
FDA Approvals
Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease
Lilly Ostrovsky
Read More
Foreword
Welcome to the Mid-Year Addendum to Our Payers’ Guide to New FDA Approvals
Read More
FDA Approvals
Skyrizi (Risankizumab-rzaa) a New Treatment Option Approved by the FDA for Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
FDA Approvals
Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations
Loretta Fala
Read More
FDA Approvals
Spravato (Esketamine) Nasal Spray First NMDA Receptor Antagonist Approved by the FDA for Adults with Treatment-Resistant Depression
Loretta Fala
Read More
FDA Approvals
Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura
Loretta Fala
Read More
FDA Approvals, Biosimilars, Dermatology
Tremfya (Guselkumab), a Novel One-Press Patient-Controlled Injection, Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
FDA Approvals
Doptelet (Avatrombopag) Receives FDA Approval for the Treatment of Patients with Chronic Immune Thrombocytopenia
Loretta Fala
Read More
Page 1 of 2
Results 1 - 10 of 11